請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59408
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 孔繁璐(Fan-Lu Kung) | |
dc.contributor.author | Tiffany Hsin-Yu Huang | en |
dc.contributor.author | 黃歆予 | zh_TW |
dc.date.accessioned | 2021-06-16T09:22:51Z | - |
dc.date.available | 2022-09-08 | |
dc.date.copyright | 2017-09-08 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-06-26 | |
dc.identifier.citation | 1. Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, et al. The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway. Natural Medicine. 1995;1(12):1291-6.
2. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proceedings of the National Academy of Sciences of the United States of America. 1985;82(12):4245-9. 3. O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. Annual review of neuroscience. 2011;34:185-204. 4. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. Journal of Biological Chemistry. 1986;261(13):6084-9. 5. Goedert M. Tau protein and neurodegeneration. Seminars in Cell & Developmental Biology. 2004;15(1):45-9. 6. Bartus R, Dean R, Beer B, Lippa A. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217(4558):408-14. 7. Hardy J, Higgins G. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184-5. 8. Ballatore C, Lee VMY, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Natural Review Neuroscience. 2007;8(9):663-72. 9. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Natural Review Neuroscience. 2015;16(6):358-72. 10. Hardy J, Selkoe DJ. The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics. Science. 2002;297(5580):353-6. 11. Yoshikai S, Sasaki H, Doh-ura K, Furuya H, Sakaki Y. Genomic organization of the human amyloid beta-protein precursor gene. Gene. 1990;87(2):257-63. 12. Tanzi RE, Wenniger JJ, Hyman BT. Cellular specificity and regional distribution of amyloid β protein precursor alternative transcripts are unaltered in Alzheimer hippocampal formation. Molecular Brain Research. 1993;18(3):246-52. 13. Anders A. Regulation of the a-secretase ADAM10 by its prodomain and proprotein convertases. The FASEB Journal. 2001. 14. Parvathy S, Hussain I, Karran EH, Turner AJ, Hooper NM. Cleavage of Alzheimer's amyloid precursor protein by α-secretase occurs at the surface of neuronal cells. Biochemistry. 1999;38(30):9728-34. 15. De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. Journal of Cell Science. 2000;113(11):1857-70. 16. Das U, Scott D, Ganguly A, Koo EH, Tang Y, Roy S. Activity-induced convergence of APP and BACE-1 in acidic microdomains via an endocytosis-dependent pathway. Neuron. 2013;79(3):447-60. 17. Huse JT, Liu K, Pijak DS, Carlin D, Lee VM-Y, Doms RW. β-Secretase processing in the trans-golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain. Journal of Biological Chemistry. 2002;277(18):16278-84. 18. Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. Journal of Biological Chemistry. 1994;269(26):17386-9. 19. Oishi M, Nairn AC, Czernik AJ, Lim GS, Isohara T, Gandy SE, et al. The cytoplasmic domain of Alzheimer's amyloid precursor protein is phosphorylated at Thr654, Ser655, and Thr668 in adult rat brain and cultured cells. Molecular Medicine. 1997;3(2):111-23. 20. Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y, et al. APP processing is regulated by cytoplasmic phosphorylation. Journal of Biological Chemistry. 2003;163(1):83-95. 21. Suzuki T, Oishi M, Marshak DR, Czernik AJ, Nairn AC, Greengard P. Cell cycle-dependent regulation of the phosphorylation and metabolism of the Alzheimer amyloid precursor protein. The EMBO Journal. 1994;13(5):1114-22. 22. Aplin AE, Gibb GM, Jacobsen JS, Gallo JM, Anderton BH. In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3β. Journal of Neurochemistry. 1996;67(2):699-707. 23. Iijima K, Ando K, Takeda S, Satoh Y, Seki T, Itohara S, et al. Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5. Journal of Neurochemistry. 2000;75(3):1085-91. 24. Ramelot TA, Nicholson LK. Phosphorylation-induced structural changes in the amyloid precursor protein cytoplasmic tail detected by NMR. Journal of Molecular Biology. 2001;307(3):871-84. 25. Ando K, Iijima KI, Elliott JI, Kirino Y, Suzuki T. Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of beta-amyloid. Journal of Biological Chemistry. 2001;276(43):40353-61. 26. Pastorino L, Sun A, Lu PJ, Zhou XZ, Balastik M, Finn G, et al. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature. 2006;440(7083):528-34. 27. Liou YC, Sun A, Ryo A, Zhou XZ, Yu ZX, Huang HK, et al. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature. 2003;424(6948):556-61. 28. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, et al. Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis. Neurobiology of Aging. 2006;27(7):918-25. 29. Segat L, Pontillo A, Annoni G, Trabattoni D, Vergani C, Clerici M, et al. PIN1 promoter polymorphisms are associated with Alzheimer's disease. Neurobiology of Aging. 2007;28(1):69-74. 30. Tong M, Jiang Y. FK506-Binding Proteins and Their Diverse Functions. Current Molecular Pharmacology. 2015;9(1):48-65. 31. Perrino BA, Ng LY, Soderling TR. Calcium regulation of calcineurin phosphatase activity by its B subunit and calmodulin. Role of the autoinhibitory domain. Journal of Biological Chemistry. 1995;270(1):340-6. 32. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature. 1992;357(6380):695-7. 33. Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes & Development. 2003;17(18):2205-32. 34. Jain J, McCaffrey PG, Miner Z, Kerppola TK, Lambert JN, Verdine GL, et al. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature. 1993;365(6444):352-5. 35. Dobashi Y, Watanabe Y, Miwa C, Suzuki S, Koyama S. Mammalian target of rapamycin: a central node of complex signaling cascades. International journal of clinical and experimental pathology. 2011;4(5):476-95. 36. Cameron AM, Nucifora FC, Jr., Fung ET, Livingston DJ, Aldape RA, Ross CA, et al. FKBP12 binds the inositol 1,4,5-trisphosphate receptor at leucine-proline (1400-1401) and anchors calcineurin to this FK506-like domain. Journal of Biological Chemistry. 1997;272(44):27582-8. 37. Van Acker K, Bultynck G, Rossi D, Sorrentino V, Boens N, Missiaen L, et al. The 12 kDa FK506-binding protein, FKBP12, modulates the Ca2+-flux properties of the type-3 ryanodine receptor. Journal of Cell Science. 2004;117(Pt 7):1129-37. 38. Cameron AM, Steiner JP, Sabatini DM, Kaplin AI, Walensky LD, Snyder SH. Immunophilin FK506 binding protein associated with inositol 1,4,5-trisphosphate receptor modulates calcium flux. Proceedings of the National Academy of Sciences of the United States of America. 1995;92(5):1784-8. 39. Timerman AP, Wiederrecht G, Marcy A, Fleischer S. Characterization of an exchange reaction between soluble FKBP-12 and the FKBP.ryanodine receptor complex. Modulation by FKBP mutants deficient in peptidyl-prolyl isomerase activity. Journal of Biological Chemistry. 1995;270(6):2451-9. 40. Foskett JK, White C, Cheung KH, Mak DO. Inositol trisphosphate receptor Ca2+ release channels. Physiol Rev. 2007;87(2):593-658. 41. Shin DW, Pan Z, Bandyopadhyay A, Bhat MB, Kim DH, Ma J. Ca2+-dependent interaction between FKBP12 and calcineurin regulates activity of the Ca2+ release channel in skeletal muscle. Biophysical journal. 2002;83(5):2539-49. 42. Cameron AM, Steiner JP, Roskams AJ, Ali SM, Ronnettt GV, Snyder SH. Calcineurin associated with the inositol 1,4,5-trisphosphate receptor-FKBP12 complex modulates Ca2+ flux. Cell. 1995;83(3):463-72. 43. Sporn M, Roberts A, Wakefield L, Assoian R. Transforming growth factor-beta: biological function and chemical structure. Science. 1986;233(4763):532-4. 44. Chen YG, Liu F, Massague J. Mechanism of TGFbeta receptor inhibition by FKBP12. The EMBO Journal. 1997;16(13):3866-76. 45. Wang T, Li B-Y, Danielson PD, Shah PC, Rockwell S, Lechleider RJ, et al. The Immunophilin FKBP12 Functions as a Common Inhibitor of the TGFβ Family Type I Receptors. Cell. 1996;86(3):435-44. 46. Giordano A, Romano S, Mallardo M, D'Angelillo A, Calì G, Corcione N, et al. FK506 can activate transforming growth factor-β signalling in vascular smooth muscle cells and promote proliferation. Cardiovascular Research. 2008;79(3):519-26. 47. Avramut M, Achim CL. Immunophilins and their ligands: insights into survival and growth of human neurons. Physiology & Behavior. 2002;77(4-5):463-8. 48. Liu FL, Liu PH, Shao HW, Kung FL. The intracellular domain of amyloid precursor protein interacts with FKBP12. Biochemical and Biophysical Research Communications. 2006;350(2):472-7. 49. Lin CC. Investigation of the effect of FKBP12-AICD interaction on APP processing. Taiwan: National Taiwan University; 2014. 50. Dineley KT, Hogan D, Zhang WR, Taglialatela G. Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiology of Learning and Memory. 2007;88(2):217-24. 51. Klee CB, Crouch TH, Krinks MH. Calcineurin: a calcium- and calmodulin-binding protein of the nervous system. Proceedings of the National Academy of Sciences of the United States of America. 1979;76(12):6270-3. 52. Tong G, Shepherd D, Jahr C. Synaptic desensitization of NMDA receptors by calcineurin. Science. 1995;267(5203):1510-2. 53. Reese LC, Zhang W, Dineley KT, Kayed R, Taglialatela G. Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. Aging cell. 2008;7(6):824-35. 54. Springer JE, Azbill RD, Nottingham SA, Kennedy SE. Calcineurin-Mediated BAD Dephosphorylation Activates the Caspase-3 Apoptotic Cascade in Traumatic Spinal Cord Injury. The Journal of Neuroscience. 2000;20(19):7246-51. 55. Numakawa T, Suzuki S, Kumamaru E, Adachi N, Richards M, Kunugi H. BDNF function and intracellular signaling in neurons. Histology and Histopathology. 2010;25(2):237-58. 56. Agostinho P, Lopes JP, Velez Z, Oliveira CR. Overactivation of calcineurin induced by amyloid-beta and prion proteins. Neurochemistry International. 2008;52(6):1226-33. 57. Utreja S, Miller SJ, Saunders A. Calcineurin overexpression regulates APP metabolism. Advances in Alzheimer's Disease. 2013;Vol.02No.03:8. 58. Simpson JE, Ince PG, Lace G, Forster G, Shaw PJ, Matthews F, et al. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiology of Aging. 2010;31(4):578-90. 59. Wu HY, Hudry E, Hashimoto T, Kuchibhotla K, Rozkalne A, Fan Z, et al. Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. Journal of Neuroscience. 2010;30(7):2636-49. 60. Ikura T, Ito N. Requirements for peptidyl-prolyl isomerization activity: A comprehensive mutational analysis of the substrate-binding cavity of FK506-binding protein 12. Protein Science : A Publication of the Protein Society. 2007;16(12):2618-25. 61. DeCenzo MT, Park ST, Jarrett BP, Aldape RA, Futer O, Murcko MA, et al. FK506-binding protein mutational analysis: defining the active-site residue contributions to catalysis and the stability of ligand complexes. Protein engineering. 1996;9(2):173-80. 62. Aldape RA, Futer O, DeCenzo MT, Jarrett BP, Murcko MA, Livingston DJ. Charged surface residues of FKBP12 participate in formation of the FKBP12-FK506-calcineurin complex. Journal of Biological Chemistry. 1992;267(23):16029-32. 63. Janowski B, Wöllner S, Schutkowski M, Fischer G. A protease-free assay for peptidyl prolylcis/trans isomerases using standard peptide substrates. Analytical Biochemistry. 1997;252(2):299-307. 64. Futer O, DeCenzo MT, Aldape RA, Livingston DJ. FK506 binding protein mutational analysis: defining the surface residue contributions to stability of the calcineurin co-complex. Journal of Biological Chemistry. 1995;270(32):18935-40. 65. Itoh S, Navia MA. Structure comparison of native and mutant human recombinant FKBP12 complexes with the immunosuppressant drug FK506 (tacrolimus). Protein Science : A Publication of the Protein Society. 1995;4(11):2261-8. 66. Kunz C, Jahreis G, Gunther R, Berger S, Fischer G, Hofmann HJ. Influence of lithium cations on prolyl peptide bonds. Journal of Peptide Science. 2012;18(6):400-4. 67. Fischer G, Bang H, Berger E, Schellenberger A. Conformational specificity of chymotrypsin toward proline-containing substrates. Biochimica et Biophysica Acta. 1984;791(1):87-97. 68. Hoffmann R, Reichert I, Wachs WO, Zeppezauer M, Kalbitzer HR. 1H and 31P NMR spectroscopy of phosphorylated model peptides. International Journal of Peptide and Protein Research. 1994;44(3):193-8. 69. Yaffe MB, Schutkowski M, Shen M, Zhou XZ, Stukenberg PT, Rahfeld JU, et al. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science. 1997;278(5345):1957-60. 70. Liu F-L, Liu T-Y, Kung F-L. FKBP12 regulates the localization and processing of amyloid precursor protein in human cell lines. Journal of Biosciences. 2014;39(1):85-95. 71. Schägger H, von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Analytical Biochemistry. 1987;166(2):368-79. 72. Schagger H. Tricine-SDS-PAGE. Nature Protocols. 2006;1(1):16-22. 73. Sastre M. Troubleshooting methods for APP processing in vitro. Journal of Pharmacological and Toxicological Methods. 2010;61(2):86-91. 74. Gronwall C, Jonsson A, Lindstrom S, Gunneriusson E, Stahl S, Herne N. Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides. Journal of Biotechnology. 2007;128(1):162-83. 75. Coughlan K, Huang X, He X, Chung CHY, Li G, Tang J. Expression and processing of fluorescent fusion proteins of amyloid precursor protein (APP). Biochimica et Biophysica acta. 2013;1833(6):1562-71. 76. Chan SL, Kim WS, Kwok JB, Hill AF, Cappai R, Rye KA, et al. ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. Journal Neurochemistry. 2008;106(2):793-804. 77. Espargaro A, Sabate R, Ventura S. Thioflavin-S staining coupled to flow cytometry. A screening tool to detect in vivo protein aggregation. Molecular bioSystems. 2012;8(11):2839-44. 78. Wild-Bode C, Yamazaki T, Capell A, Leimer U, Steiner H, Ihara Y, et al. Intracellular generation and accumulation of amyloid beta-peptide terminating at amino acid 42. Journal of Biological Chemistry. 1997;272(26):16085-8. 79. Buxbaum JD, Ruefli AA, Parker CA, Cypess AM, Greengard P. Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(10):4489-93. 80. Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron. 2008;59(2):214-25. 81. Lanner JT, Georgiou DK, Joshi AD, Hamilton SL. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harbor Perspectives in Biology. 2010;2. 82. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. Journal of Biological Chemistry. 2005;280. 83. Cheung KH, Shineman D, Muller M, Cardenas C, Mei L, Yang J, et al. Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron. 2008;58(6):871-83. 84. Querfurth HW, Jiang J, Geiger JD, Selkoe DJ. Caffeine stimulates amyloid beta-peptide release from beta-amyloid precursor protein-transfected HEK293 cells. Journal of Neurochemistry. 1997;69. 85. Cheung KH, Shineman D, Muller M, Cardenas C, Mei L, Yang J, et al. Mechanism of Ca2+ disruption in Alzheimer’s disease by presenilin regulation of InsP(3) receptor channel gating. Neuron. 2008;58. 86. Vogel T, Ahrens S, Büttner N, Krieglstein K. Transforming growth factor β promotes neuronal cell fate of mouse cortical and hippocampal progenitors in vitro and in vivo: identification of Nedd9 as an essential signaling component. Cerebral Cortex (New York, NY). 2010;20(3):661-71. 87. Tesseur I, Zou K, Esposito L, Bard F, Berber E, Can JV, et al. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. Journal of Clinical Investigation. 2006;116(11):3060-9. 88. Dawkins E, Small DH. Insights into the physiological function of the β-amyloid precursor protein: beyond Alzheimer's disease. Journal of Neurochemistry. 2014;129(5):756-69. 89. Lazarov O, Demars M. All in the Family: How the APPs Regulate Neurogenesis. Frontiers in Neuroscience. 2012;6(81). 90. Ikura T, Kinoshita K, Ito N. A cavity with an appropriate size is the basis of the PPIase activity. Protein Eng Des Sel. 2008;21(2):83-9. 91. Yamazaki S, Yamaji T, Murai N, Yamamoto H, Price RD, Matsuoka N, et al. FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy. Neuropharmacology. 2008;55(7):1226-30. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59408 | - |
dc.description.abstract | 阿茲海默症 (Alzheimer’s disease,AD) 為一常見的神經退化性疾病,其中一項病理特徵為在細胞間隙堆積的老年斑塊 (senile plaques),由類澱粉前驅蛋白 (amyloid precursor protein,APP) 經酵素循序切割水解後產生的 amyloid-β (Aβ) 所組成。過去研究發現APP上的Thr668經磷酸化後會提高Thr668-Pro669間胜肽鍵cis構型的比例,並與Aβ的產生呈正相關。
實驗室過去發現一具有PPIase 活性的免疫親合素FK506-Binding-Protein12 (FKBP12) 與類澱粉前驅蛋白胞內區塊 (APP intracellular domain,AICD) 有交互作用,並使得APP的代謝途徑走向amyloidogenic pathway。透過FKBP12的突變株,證實FKBP12對APP代謝的影響與其PPIase活性有關,推測FKBP12可能透過催化APP上Thr668-Pro669胜肽鍵的構形由trans到cis form,進而影響APP的水解途徑。為確認此假說,利用以Ala取代APP上Pro669而產生一無法被FKBP12進行胜肽鍵構形催化的突變株,以及FKBP12 PPIase活性缺陷突變株,可釐清FKBP12影響APP代謝背後的分子機轉。同時,各FKBP12的活性則以chymotrypsin-free assay確認。前人的研究發現,在細胞中給予FK506可以反轉過度表現FKBP12的效果,其機轉可能是干擾FKBP12與AICD的交互作用,同時抑制FKBP12 PPIase 活性。然過去的研究指出FK506的神經保護作用與其對calcineurin的抑制有關,為了解calcineurin是否參與所觀察到FKBP12-mediated的APP水解調控,FKBP12突變株FKBP12R42I與FK506衍生物FK1706將用於實驗中來釐清此問題。 在本實驗當中,以快速蛋白質液相層析系統 (fast protein liquid chromatography,FPLC)純化出七個具不同 PPIase activity的FKBP12蛋白。然而在以chymotrypsin-free assay測定FKBP12的PPIase activity實驗當中,並未測得因受質胜肽鍵構形改變而產生在330 nm波長下的吸收變化,其原因可能來自FKBP12在純化過程中活性的降低,亦或是儀器靈敏度不足。在探討APP代謝是否受FKBP12 PPIase活性影響的部分,APP兩代謝途徑中產物C99和C83的比例,可指出APP代謝途徑受FKBP12作用的改變。然而 C99和C83分子量的差距極小,實驗中未能以西方墨點法成功分離兩者,因此無法確認本實驗的假說。 針對上述實驗的瓶頸,可改以NMR 和chymotrypsin assay分析FKBP12 之PPIase 活性。在APP代謝的部分,則在本論文中針對西方墨點法的步驟以及可能的替代方法進行討論,以用於未來的改善。 | zh_TW |
dc.description.abstract | Alzheimer’s disease (AD) is a common neurodegenerative disease with the pathological symptom of extracellular senile plaques composed of amyloid-β (Aβ), a serial processed product of amyloid precursor protein (APP). Accumulating evidences have shown that phosphorylation at Thr668 causes an increase of cis form Thr668-Pro669 peptide bond in APP and is correlated with Aβ generation.
FKBP12, an immunophilin with PPIase isomerase activity, was found to interact with APP intracellular domain (AICD) and shift APP metabolism to amyloidogenic pathway. A subsequent study using FKBP12 mutants revealed that the effect of FKBP12 on the regulation of APP processing corresponded to its PPIase activity, indicating that FKBP12 might catalyze Thr668-Pro669 peptide bond conformation from trans to cis form. To confirm this hypothesis, APPP669A, a mutant which cannot be catalyzed by FKBP12 due to the substitution of Pro669 with Ala, and PPIase activity-deficient FKBP12 were used to elucidate the molecular mechanism of the effect of FKBP12 on APP processing. Additionally, the PPIase activity was attempted to be evaluated by chymotrypsin-free assay. A Previous study also showed that the effect of FKBP12 can be reversed by the presence of FK506, which may cause the disruption of AICD-FKBP12 interaction and, at the same time, the inhibition of PPIase activity. However, the neuroprotective effect of FK506 has been linked to the inhibition of calcineurin. To elucidate whether or not calcineurin is involved in the FKBP12-mediated APP processing, FKBP12 mutant, FKBP12R42I, and FK1706, a FK506 derivate, are used to address this question. Seven FKBP12 with different PPIase activity were purified using fast protein liquid chromatography (FPLC). While the PPIase activity of purified FKBP12 cannot be validated by detecting the 330 nm absorbance differences between cis and trans form substrates in chymotrypsin-free assay. The failure can be due to the loss of protein activities during purification process and/or the sensitivity limitation of a UV/VIS spectrum. The ratio of the two products, C99 and C83, generated by processed APP in two different pathways were used to verify the shifting of APP metabolism under the effect of FKBP12. However, C99 and C83 signals on western blot cannot be successfully distinguished due to the small size difference between each two. Therefore, the hypothesis of the role of FKBP12 in APP processing cannot be confirmed by the conducted experiment. To improve this study, NMR and chymotrypsin assay can be applied to verified the PPIase activity of FKBP12. Also, the improvement of western blot procedures and alternative methods to observe APP processing are discussed. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T09:22:51Z (GMT). No. of bitstreams: 1 ntu-106-R03423012-1.pdf: 2070493 bytes, checksum: 448bc4b5348de97bdd0f0800090b31f6 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 口試委員會審定書 I
致謝 II 中文摘要 III Abstract V Abbreviations VII Introduction 1 Aim 9 Materials and Methods 11 Results and Discussion 21 1. Characterize the PPIase activity of FKBP12 wt and mutants 21 2. Evaluate the effect of FKBP12 wt and FKBP12W59A on APP and APPP669A processing 26 3. Whether or not CaN is involved in APP processing through interactions with FKBP12-AICD complex 27 4. Alternative approach to detect APP processing 29 5. FKBP12 signaling pathway 31 Figures 33 Tables 50 References 52 | |
dc.language.iso | en | |
dc.title | 探討FKBP12對APP代謝之影響 | zh_TW |
dc.title | Elucidation of the Effects of FKBP12 on APP Processing | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 許麗卿(Lih-Ching Hsu),忻凌偉(Ling-Wei Hsin) | |
dc.subject.keyword | 阿茲海默症,類澱粉前驅蛋白,FKBP12,PPIase,FK506,calcineurin, | zh_TW |
dc.subject.keyword | Alzheimer's disease,Amyloid Precursor Protein,FKBP12,PPIase,FK506,calcineurin, | en |
dc.relation.page | 60 | |
dc.identifier.doi | 10.6342/NTU201701054 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-06-26 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 2.02 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。